NYU Langone Health

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).

1,164 total trials 197 currently recruiting 741 completed early-phase tilt top decile by trial count

NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.

NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.

Top-decile sponsor footprint

NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 53/100

741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,164 total, page 22 of 24

COMPLETED

Hypertension and Sleep Disordered Breathing in Pediatrics

NCT00990899

COMPLETED NA

Trial of Educational Outcomes of WISE-MD

NCT01322230

COMPLETED

Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance

NCT01180361

COMPLETED Phase 4

Study of Wound Packing After Superficial Skin Abscess Drainage

NCT00746109

COMPLETED

A Comparative Trial of Standard 12 Lead ECG to the 12 Lead ECG Glove to Assess Cardiac Electrical Function

NCT01218334

COMPLETED Phase 1

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

NCT00708916

TERMINATED

Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer

NCT00933088

TERMINATED Phase 2

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

NCT00848783

COMPLETED Phase 3

Counseling Older Adults to Control Hypertension

NCT01180673

COMPLETED Phase 1

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

NCT00846612

TERMINATED NA

Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia

NCT00895063

COMPLETED Phase 1

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NCT01372644

TERMINATED Phase 2

A Pilot Study of Metabolic Effects of Omentectomy

NCT00565799

COMPLETED Phase 2

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

NCT00696696

COMPLETED NA

Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation

NCT02272400

COMPLETED Phase 4

A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall

NCT00468143

COMPLETED Phase 1

Intervening With and Improving Care for Patients at Risk for Frequent Hospital Admissions

NCT01292096

COMPLETED Phase 4

Extended-release Naltrexone for Alcohol Dependence in Primary Care

NCT00620750

COMPLETED Phase 1

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

NCT00571922

COMPLETED Phase 2

Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate

NCT00483327

TERMINATED

Non Invasive Biomarkers to Identify Subjects at Risk for Preterm Delivery

NCT00919412

COMPLETED Early Phase 1

Preventive IVIG Therapy for Congenital Heart Block

NCT00460928

COMPLETED NA

Immediate vs. Delayed Insertion of Copper T 380A IUD After Termination of Pregnancy Over 12-weeks Gestation

NCT00540046

TERMINATED Phase 2

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

NCT00483119

TERMINATED Phase 2

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

NCT00840450

COMPLETED NA

Jet Lidocaine for Pain Relief During Needle Insertion in a Pediatric Emergency Department

NCT00681902

COMPLETED NA

Parent Training for Attention Deficit Hyperactivity Disorder (ADHD) Preschoolers

NCT01320098

COMPLETED Phase 1

A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis

NCT00563212

COMPLETED

Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women

NCT00883272

TERMINATED Phase 2

Telephone-Based Lifestyle Intervention to Reduce Blood Pressure in Prehypertensive Patients

NCT00583310

COMPLETED

Continuous Glucose Monitoring in Type 2 Diabetes Mellitus

NCT01083043

COMPLETED

Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness

NCT00393913

COMPLETED NA

Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder

NCT00381407

COMPLETED Phase 4

Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training

NCT00120874

COMPLETED Phase 1

Improving Parental Understanding of Medication Instructions Through a Pictogram-Based Intervention

NCT00537433

COMPLETED

Psychiatric and Cognitive Manifestations of Parkinson's Disease

NCT00360633

COMPLETED

Transfer of Grasp Control Across Hands After Stroke

NCT00589368

COMPLETED

Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb

NCT00212550

COMPLETED Phase 4

Detecting an Early Response to Donepezil With Measures of Visual Attention

NCT03073876

COMPLETED NA

Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening

NCT00836303

COMPLETED NA

Promoting Early School Readiness in Primary Health Care

NCT00212576

COMPLETED Phase 2

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

NCT00528437

COMPLETED

Novel Diagnostics With Optical Coherence Tomography: Imaging the Anterior Eye

NCT00343473

COMPLETED Phase 4

Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT00241176

COMPLETED NA

ParentCorps: Promoting Healthy Development in Children From Low Income Communities

NCT01670227

COMPLETED Phase 2

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

NCT00857246

COMPLETED NA

Lap-Band Surgery on Adolescents for Safety and Efficacy

NCT00587301

COMPLETED Phase 3

Family Approach to Managing Asthma in Early Teens

NCT00241852

TERMINATED Phase 4

Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder

NCT00391430

TERMINATED Phase 1

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

NCT00861471

← Previous Page 22 of 24 Next →

Phase Distribution

PhaseTrial count
Phase 1 99
Phase 2 132
Phase 3 28
Phase 4 95

What is open in the NYU Langone Health pipeline

197 recruiting of 1,164 indexed (17% open); 741 completed (64%).

Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

NYU Langone Health: open-pipeline peers nationwide

Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 15%16%17%18%19% Total trials Recruiting share NYU Langone HealthUniversity of Alabama at BirminghamWake Forest University Health SciencesEmory UniversityNorthwestern UniversityCSL BehringPenn State UniversityUniversity of HawaiiUniversity of Utah
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,164 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this NYU Langone Health page

1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.

  • 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.